Kalaris Therapeutics, Inc.
Moat Score — Kalaris Therapeutics, Inc.
Total Moat Score
5 / 30
| Moat Factor | Score | Analysis |
|---|---|---|
| Intangible Assets Patents, trademarks, brand strength, or regulatory licenses that protect a company's products or services from being freely copied by competitors. | 3 / 5 | Kalaris's rights derive from a licensed UCSD patent estate tied to Dr. Napoleone Ferrara's anti-VEGF research, and its lead molecule TH103 showed a differentiated pharmacokinetic profile (27-51x lower plasma Cmax) in Phase 1a data. This is real, scientifically credible IP, but it remains clinical-stage and unproven at Phase 3, so it is bounded rather than dominant. |
| Cost Advantage A durable ability to produce goods or services more cheaply than competitors — through scale, unique access to cheap inputs, location, or process — that lets a company undercut rivals or out-earn them at the same price. | 0 / 5 | Kalaris owns no manufacturing facilities and relies entirely on third-party contract manufacturers, with no evidence of a structural cost edge; in fact, a 2025 tolerability issue was attributed to host-cell protein manufacturing impurities, which is a cost/quality risk, not an advantage. |
| Pricing Power The ability to raise prices without losing meaningful business, because the product or service is differentiated, mission-critical, or has few good substitutes. | 1 / 5 | With zero current revenue and no approved product, Kalaris has no demonstrated pricing power. Any eventual pricing power would be contingent on TH103 differentiating against entrenched, price-competitive anti-VEGF biosimilars from Roche and Regeneron, which is unproven. |
| Network Effect The product or service becomes more valuable to every user as more people or organizations use it, making an established leader harder to displace. | 0 / 5 | As a single-asset ophthalmology drug developer, Kalaris's business has no network effect; TH103's value to one patient or physician does not increase as more patients or physicians adopt it. |
| Switching Costs The money, time, or operational disruption a customer would face switching to a competitor, which locks in existing customers and supports renewals. | 1 / 5 | Retina specialists and patients already established on approved anti-VEGF therapies like Eylea or Vabysmo face real inertia, but this works against Kalaris today rather than for it; TH103 has no installed base yet, so switching-cost moat is only theoretical and would need strong Phase 3 data to materialize. |
| Efficient Scale A market that can only profitably support a small number of players, so incumbents face limited threat from new entrants even without other defenses. | 0 / 5 | The nAMD and broader retinal disease market is large and well-served by Roche, Regeneron, and Novartis, with ample room for the biosimilar wave; there is no efficient-scale dynamic limiting the number of viable competitors in this space. |